ipratropium ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
atropine derivatives 1475 60205-81-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • ipratropium
  • ipratropium bromide
  • ipratropium bromide hydrate
  • ipratropium bromide monohydrate
A muscarinic antagonist structurally related to ATROPINE but often considered safer and more effective for inhalation use. It is used for various bronchial disorders, in rhinitis, and as an antiarrhythmic.
  • Molecular weight: 332.46
  • Formula: C20H30NO3
  • CLOGP: -2.19
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 1
  • TPSA: 46.53
  • ALOGS: -5.48
  • ROTB: 6

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.24 mg N
0.12 mg Inhal.aerosol
0.12 mg Inhal.powder
0.30 mg Inhal.solution

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.01 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 3 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 5.10 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 31.40 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.95 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.64 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Dec. 29, 1986 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Asthma 1159.58 10.79 839 48159 88498 50467628
Wheezing 697.25 10.79 535 48463 61512 50494614
Obstructive airways disorder 455.30 10.79 246 48752 15406 50540720
Dyspnoea 416.03 10.79 1315 47683 546293 50009833
Chronic obstructive pulmonary disease 410.68 10.79 370 48628 53065 50503061
Sleep disorder due to a general medical condition 292.98 10.79 143 48855 7228 50548898
Productive cough 209.98 10.79 257 48741 52437 50503689
Full blood count abnormal 209.84 10.79 177 48821 23211 50532915
Pneumonia 205.06 10.79 815 48183 377586 50178540
Cough 194.35 10.79 593 48405 240671 50315455
Chest discomfort 165.68 10.79 311 48687 92411 50463715
Drug intolerance 125.78 10.79 29 48969 219075 50337051
Therapeutic product effect incomplete 114.24 10.79 265 48733 91250 50464876
Drug ineffective 114.21 10.79 410 48588 818923 49737203
Nasal congestion 113.93 10.79 189 48809 50931 50505195
Completed suicide 113.61 10.79 3 48995 131886 50424240
Contraindicated product administered 110.45 10.79 9 48989 148949 50407177
Respiratory failure 109.42 10.79 260 48738 90921 50465205
Alopecia 108.22 10.79 51 48947 244996 50311130
Breath sounds abnormal 104.84 10.79 75 48923 7717 50548409
Synovitis 99.18 10.79 5 48993 123860 50432266
Pemphigus 99.00 10.79 4 48994 120162 50435964
Rheumatoid arthritis 97.67 10.79 37 48961 202513 50353613
Systemic lupus erythematosus 97.64 10.79 11 48987 140611 50415515
Sputum discoloured 91.61 10.79 87 48911 13308 50542818
Dyspnoea exertional 87.91 10.79 169 48829 51064 50505062
Loss of personal independence in daily activities 83.20 10.79 199 48799 69851 50486275
Glossodynia 82.90 10.79 8 48990 115561 50440565
Treatment failure 81.40 10.79 17 48981 137620 50418506
Arthropathy 80.99 10.79 26 48972 157880 50398246
Nasal turbinate hypertrophy 78.08 10.79 28 48970 642 50555484
Bronchial neoplasm 77.63 10.79 25 48973 408 50555718
Ventricular failure 73.21 10.79 23 48975 345 50555781
Bronchial haemorrhage 73.14 10.79 25 48973 495 50555631
Hypercapnia 72.72 10.79 49 48949 4578 50551548
Sleep apnoea syndrome 72.61 10.79 102 48896 23766 50532360
Hyper IgE syndrome 69.48 10.79 23 48975 411 50555715
Rhonchi 69.11 10.79 37 48961 2270 50553856
Toxicity to various agents 68.40 10.79 63 48935 212436 50343690
Upper-airway cough syndrome 65.17 10.79 59 48939 8491 50547635
Bronchospasm 64.94 10.79 76 48922 14778 50541348
Wound 64.79 10.79 12 48986 105782 50450344
Acute respiratory failure 63.54 10.79 106 48892 28676 50527450
Maternal exposure during pregnancy 63.49 10.79 38 48960 159740 50396386
Hepatic enzyme increased 63.08 10.79 27 48971 137353 50418773
Blood test abnormal 61.70 10.79 65 48933 11254 50544872
Respiration abnormal 61.60 10.79 46 48952 5056 50551070
Endometrial ablation 60.80 10.79 25 48973 838 50555288
Joint swelling 60.39 10.79 90 48908 245196 50310930
Infusion related reaction 58.53 10.79 47 48951 169510 50386616
Forced expiratory volume decreased 58.44 10.79 42 48956 4352 50551774
Middle insomnia 57.73 10.79 59 48939 9862 50546264
Off label use 57.72 10.79 250 48748 474176 50081950
Bronchitis 57.37 10.79 226 48772 103933 50452193
Rhinitis 55.03 10.79 53 48945 8248 50547878
Pericarditis 54.99 10.79 6 48992 78683 50477443
Prolonged expiration 54.61 10.79 22 48976 699 50555427
Abdominal discomfort 54.14 10.79 88 48910 231553 50324573
Bronchial disorder 54.07 10.79 25 48973 1117 50555009
Rales 53.86 10.79 57 48941 9921 50546205
Arthralgia 53.45 10.79 231 48767 438471 50117655
Restrictive pulmonary disease 51.74 10.79 26 48972 1398 50554728
Pain 51.55 10.79 339 48659 578564 49977562
Hypoxia 51.03 10.79 136 48862 50987 50505139
Therapeutic product effect decreased 50.44 10.79 35 48963 136015 50420111
Rash 48.73 10.79 238 48760 437233 50118893
Cardiac murmur 48.52 10.79 56 48942 10728 50545398
Asthma-chronic obstructive pulmonary disease overlap syndrome 48.47 10.79 18 48980 457 50555669
Oxygen saturation decreased 47.90 10.79 168 48830 73080 50483046
Heart sounds 46.95 10.79 19 48979 611 50555515
PO2 decreased 46.64 10.79 24 48974 1357 50554769
Eosinophilia 45.66 10.79 72 48926 18580 50537546
Discomfort 45.60 10.79 24 48974 108356 50447770
Haemoptysis 44.64 10.79 85 48913 25488 50530638
Blood immunoglobulin E increased 44.47 10.79 28 48970 2331 50553795
Bronchiectasis 43.93 10.79 52 48946 10231 50545895
Throat clearing 43.90 10.79 22 48976 1176 50554950
Exposure during pregnancy 43.71 10.79 32 48966 120983 50435143
Sight disability 43.57 10.79 12 48986 110 50556016
Swelling 43.56 10.79 80 48918 200792 50355334
Lower respiratory tract infection 43.40 10.79 195 48803 95006 50461120
Drug abuse 43.28 10.79 4 48994 59842 50496284
Anti-cyclic citrullinated peptide antibody positive 43.22 10.79 8 48990 70579 50485547
PCO2 increased 41.92 10.79 21 48977 1122 50555004
Myocardial infarction 41.82 10.79 184 48814 88843 50467283
Tachypnoea 40.97 10.79 60 48938 14517 50541609
Oesophageal spasm 40.17 10.79 26 48972 2270 50553856
Sinus tachycardia 39.79 10.79 73 48925 21281 50534845
Gastrooesophageal reflux disease 39.01 10.79 162 48836 76266 50479860
Venous pressure jugular increased 39.01 10.79 16 48982 533 50555593
Thermohypoaesthesia 38.90 10.79 11 48987 112 50556014
Influenza B virus test positive 37.95 10.79 13 48985 259 50555867
Vocal cord dysfunction 37.90 10.79 14 48984 350 50555776
Total lung capacity increased 37.84 10.79 17 48981 710 50555416
Upper respiratory tract infection 37.08 10.79 144 48854 65754 50490372
Lung hyperinflation 36.52 10.79 19 48979 1099 50555027
Status asthmaticus 35.63 10.79 17 48981 816 50555310
Cardiac failure congestive 35.61 10.79 169 48829 84213 50471913
Pulmonary hypertension 35.49 10.79 91 48907 33326 50522800
Breast conserving surgery 35.23 10.79 17 48981 837 50555289
Rib deformity 35.20 10.79 11 48987 162 50555964
Respiratory rate increased 35.14 10.79 49 48949 11336 50544790
Respiratory disorder 34.24 10.79 86 48912 31101 50525025
Infective pulmonary exacerbation of cystic fibrosis 33.80 10.79 40 48958 7869 50548257
Oesophageal pain 33.24 10.79 25 48973 2777 50553349
Tracheomalacia 33.22 10.79 10 48988 129 50555997
Airway peak pressure increased 33.14 10.79 12 48986 283 50555843
Nasal polyps 33.02 10.79 24 48974 2530 50553596
Sinus disorder 33.01 10.79 62 48936 18396 50537730
Multimorbidity 32.83 10.79 14 48984 515 50555611
Dysphonia 32.47 10.79 97 48901 38795 50517331
Helicobacter infection 31.82 10.79 5 48993 49697 50506429
Polycystic ovaries 31.34 10.79 23 48975 2461 50553665
Respiratory distress 31.32 10.79 82 48916 30407 50525719
Total lung capacity decreased 31.26 10.79 18 48980 1273 50554853
Infective exacerbation of chronic obstructive airways disease 31.05 10.79 17 48981 1091 50555035
Blood insulin abnormal 30.97 10.79 7 48991 25 50556101
FEV1/FVC ratio decreased 30.82 10.79 8 48990 57 50556069
Granuloma 30.30 10.79 30 48968 4828 50551298
Rhinitis allergic 30.08 10.79 36 48962 7164 50548962
Bronchopulmonary aspergillosis allergic 29.90 10.79 17 48981 1174 50554952
Nasal obstruction 29.32 10.79 16 48982 1020 50555106
Heart rate increased 29.23 10.79 150 48848 77100 50479026
Bundle branch block left 29.12 10.79 33 48965 6197 50549929
Lung disorder 28.63 10.79 102 48896 44697 50511429
Cyanosis 28.41 10.79 52 48946 15132 50540994
Type 2 diabetes mellitus 28.01 10.79 85 48913 34290 50521836
Atrial fibrillation 27.69 10.79 181 48817 101564 50454562
Drug hypersensitivity 27.62 10.79 137 48861 250873 50305253
Asthmatic crisis 27.41 10.79 18 48980 1610 50554516
Respiratory acidosis 26.61 10.79 31 48967 5997 50550129
Lactose intolerance 26.28 10.79 21 48977 2549 50553577
Kyphosis 26.17 10.79 20 48978 2275 50553851
Separation anxiety disorder 26.01 10.79 6 48992 24 50556102
Blister 25.51 10.79 27 48971 85391 50470735
Affective disorder 25.17 10.79 28 48970 5153 50550973
Diarrhoea 25.12 10.79 410 48588 588066 49968060
Dyslipidaemia 25.12 10.79 30 48968 5958 50550168
Abortion spontaneous 25.01 10.79 5 48993 41767 50514359
Blood pH decreased 24.98 10.79 20 48978 2435 50553691
Intentional overdose 24.62 10.79 15 48983 62489 50493637
Respiratory gas exchange disorder 24.30 10.79 10 48988 336 50555790
Reversible airways obstruction 24.11 10.79 14 48984 1006 50555120
Product use issue 23.94 10.79 70 48928 149405 50406721
Irritable bowel syndrome 23.77 10.79 10 48988 51431 50504695
Psoriatic arthropathy 23.64 10.79 8 48990 47024 50509102
Pneumonia viral 23.50 10.79 31 48967 6803 50549323
Injection site pain 23.35 10.79 45 48953 110979 50445147
Pulmonary function test decreased 23.15 10.79 22 48976 3366 50552760
Blood bicarbonate decreased 23.15 10.79 20 48978 2705 50553421
Amaurosis 23.03 10.79 11 48987 529 50555597
Acute generalised exanthematous pustulosis 22.57 10.79 35 48963 8903 50547223
Respiratory tract infection 22.28 10.79 75 48923 31942 50524184
Intentional product use issue 22.21 10.79 25 48973 76893 50479233
Laryngeal stenosis 21.70 10.79 12 48986 785 50555341
Rectal prolapse 21.63 10.79 16 48982 1733 50554393
Optic ischaemic neuropathy 21.53 10.79 13 48985 1004 50555122
Rhinorrhoea 21.53 10.79 103 48895 51480 50504646
Brain hypoxia 21.44 10.79 10 48988 456 50555670
Oesophageal motility disorder 21.39 10.79 9 48989 320 50555806
Liver disorder 21.17 10.79 5 48993 37217 50518909
Chest pain 21.16 10.79 263 48735 176619 50379507
Coronary artery disease 21.01 10.79 70 48928 29656 50526470
Injection site bruising 20.80 10.79 5 48993 36763 50519363
Emphysema 20.75 10.79 34 48964 9059 50547067
Sleep disorder due to general medical condition, insomnia type 20.50 10.79 3 48995 31444 50524682
Depressive symptom 20.40 10.79 20 48978 3180 50552946
Aspiration 20.28 10.79 34 48964 9230 50546896
Blood lactic acid increased 20.24 10.79 26 48972 5559 50550567
Crystal arthropathy 20.20 10.79 8 48990 243 50555883
Frustration tolerance decreased 19.91 10.79 26 48972 5648 50550478
Peak expiratory flow rate abnormal 19.89 10.79 6 48992 78 50556048
Injection site reaction 19.71 10.79 12 48986 50020 50506106
Fatigue 19.57 10.79 529 48469 707072 49849054
Febrile neutropenia 19.33 10.79 41 48957 97626 50458500
Oropharyngeal discomfort 19.00 10.79 21 48977 3837 50552289
Unresponsive to stimuli 18.96 10.79 69 48929 30540 50525586
Humidity intolerance 18.79 10.79 8 48990 293 50555833
Impaired healing 18.75 10.79 24 48974 69762 50486364
Hypoventilation 18.72 10.79 21 48977 3900 50552226
Eye pruritus 18.67 10.79 39 48959 12495 50543631
Neuromyelitis optica spectrum disorder 18.64 10.79 11 48987 815 50555311
Eosinophil count abnormal 18.52 10.79 9 48989 450 50555676
Pupillary reflex impaired 18.45 10.79 15 48983 1866 50554260
Haematoma 18.25 10.79 68 48930 30442 50525684
Knee arthroplasty 18.19 10.79 6 48992 35840 50520286
Dystrophic calcification 17.88 10.79 6 48992 112 50556014
Sneezing 17.86 10.79 41 48957 14003 50542123
Hip arthroplasty 17.48 10.79 4 48994 30425 50525701
Influenza 17.35 10.79 147 48851 89391 50466735
Pulmonary oedema 17.12 10.79 93 48905 48845 50507281
Nausea 17.07 10.79 537 48461 704861 49851265
Injection site erythema 16.98 10.79 29 48969 74907 50481219
Nephrocalcinosis 16.97 10.79 11 48987 963 50555163
Appetite disorder 16.94 10.79 25 48973 6089 50550037
Heparin-induced thrombocytopenia 16.85 10.79 20 48978 3945 50552181
Lymphoedema 16.76 10.79 31 48967 9091 50547035
Red blood cell sedimentation rate increased 16.64 10.79 4 48994 29412 50526714
Upper airway obstruction 16.63 10.79 9 48989 564 50555562
Infusion site erythema 16.47 10.79 30 48968 8697 50547429
Malaise 16.40 10.79 433 48565 335099 50221027
Gastrointestinal disorder 16.03 10.79 43 48955 94413 50461713
Pneumonia staphylococcal 15.96 10.79 16 48982 2613 50553513
Staphylococcus test positive 15.85 10.79 18 48980 3388 50552738
Lung opacity 15.80 10.79 14 48984 1959 50554167
Lactic acidosis 15.69 10.79 69 48929 33286 50522840
Pneumonia respiratory syncytial viral 15.57 10.79 9 48989 641 50555485
C-reactive protein abnormal 15.30 10.79 4 48994 27805 50528321
Extensor plantar response 15.28 10.79 11 48987 1143 50554983
Glycosylated haemoglobin decreased 15.20 10.79 8 48990 474 50555652
Acute myocardial infarction 14.89 10.79 62 48936 29211 50526915
Respiratory alkalosis 14.69 10.79 15 48983 2504 50553622
Sputum purulent 14.66 10.79 10 48988 953 50555173
Pneumonia haemophilus 14.54 10.79 8 48990 518 50555608
Vascular parkinsonism 14.31 10.79 5 48993 106 50556020
Facial discomfort 14.30 10.79 4 48994 39 50556087
Hepatic function abnormal 14.09 10.79 7 48991 32674 50523452
Oedema peripheral 14.09 10.79 223 48775 157738 50398388
Chest X-ray abnormal 13.94 10.79 18 48980 3867 50552259
Skin lesion 13.90 10.79 57 48941 26670 50529456
Sinusitis 13.81 10.79 237 48761 170321 50385805
Hypertrophic cardiomyopathy 13.78 10.79 11 48987 1334 50554792
Idiopathic intracranial hypertension 13.72 10.79 14 48984 2335 50553791
Peak expiratory flow rate decreased 13.71 10.79 8 48990 580 50555546
Presyncope 13.70 10.79 53 48945 24145 50531981
Stress cardiomyopathy 13.49 10.79 26 48972 7861 50548265
Hyperlactacidaemia 13.31 10.79 14 48984 2419 50553707
Lung neoplasm malignant 13.28 10.79 39 48959 15445 50540681
Sarcoidosis 13.16 10.79 20 48978 4997 50551129
Stomatitis 13.13 10.79 52 48946 101292 50454834
Peripheral swelling 12.99 10.79 132 48866 205804 50350322
Pancytopenia 12.98 10.79 40 48958 83990 50472136
Pharyngeal mass 12.98 10.79 6 48992 268 50555858
Forced expiratory volume increased 12.81 10.79 3 48995 13 50556113
Psoriasis 12.80 10.79 30 48968 68970 50487156
Tachycardia 12.64 10.79 150 48848 99613 50456513
Inspiratory capacity decreased 12.49 10.79 4 48994 64 50556062
Respiratory tract congestion 12.41 10.79 36 48962 14163 50541963
Forced expiratory volume abnormal 12.16 10.79 4 48994 70 50556056
Laryngospasm 12.16 10.79 14 48984 2674 50553452
Vocal cord disorder 12.07 10.79 10 48988 1278 50554848
Cardiac disorder 12.01 10.79 77 48921 42902 50513224
Visceral pain 12.00 10.79 3 48995 18 50556108
Blood albumin decreased 11.99 10.79 34 48964 13202 50542924
Infusion site extravasation 11.94 10.79 23 48975 6953 50549173
Drug eruption 11.89 10.79 4 48994 23602 50532524
False positive investigation result 11.87 10.79 7 48991 518 50555608
Bone marrow failure 11.78 10.79 6 48992 27618 50528508
Pneumonia pseudomonal 11.71 10.79 12 48986 2011 50554115
Angle closure glaucoma 11.66 10.79 12 48986 2022 50554104
Chondrocalcinosis pyrophosphate 11.63 10.79 9 48989 1043 50555083
Foetal exposure during pregnancy 11.58 10.79 6 48992 27353 50528773
Blood glucose abnormal 11.42 10.79 22 48976 6650 50549476
Dysaesthesia 11.41 10.79 16 48982 3719 50552407
Abscess 11.35 10.79 35 48963 14237 50541889
Shock haemorrhagic 11.32 10.79 25 48973 8319 50547807
Multiple sclerosis relapse 11.31 10.79 15 48983 42949 50513177
Catarrh 11.25 10.79 6 48992 365 50555761
Cardiac asthma 11.18 10.79 4 48994 91 50556035
Tumour hyperprogression 11.14 10.79 4 48994 92 50556034
Tongue exfoliation 10.98 10.79 4 48994 96 50556030
Musculoskeletal stiffness 10.97 10.79 76 48922 128405 50427721
Barrett's oesophagus 10.92 10.79 7 48991 601 50555525
Generalised tonic-clonic seizure 10.80 10.79 6 48992 26304 50529822

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Asthma 618.73 11.23 430 35852 33419 29504826
Wheezing 429.48 11.23 343 35939 32897 29505348
Chronic obstructive pulmonary disease 378.91 11.23 349 35933 40606 29497639
Obstructive airways disorder 305.15 11.23 182 36100 10834 29527411
Dyspnoea 300.75 11.23 979 35303 325753 29212492
Asthma-chronic obstructive pulmonary disease overlap syndrome 192.18 11.23 60 36222 683 29537562
Full blood count abnormal 170.77 11.23 144 36138 14869 29523376
Sputum discoloured 155.08 11.23 98 36184 6465 29531780
Cough 147.88 11.23 414 35868 126313 29411932
Appendicolith 132.93 11.23 71 36211 3409 29534836
Nasal obstruction 127.87 11.23 41 36241 512 29537733
Pulmonary function test decreased 126.34 11.23 73 36209 4090 29534155
Sinus pain 120.50 11.23 40 36242 561 29537684
Pneumonia 111.21 11.23 721 35561 319451 29218794
Bronchiectasis 109.29 11.23 79 36203 6506 29531739
Chest discomfort 101.06 11.23 193 36089 45790 29492455
Productive cough 98.63 11.23 154 36128 31105 29507140
Stress 94.48 11.23 124 36158 21366 29516879
Forced expiratory volume decreased 89.83 11.23 51 36231 2762 29535483
Appendicitis 85.29 11.23 77 36205 8702 29529543
Mycobacterium avium complex infection 80.27 11.23 44 36238 2225 29536020
Emphysema 74.47 11.23 71 36211 8600 29529645
Cardiogenic shock 72.65 11.23 103 36179 19087 29519158
Completed suicide 72.18 11.23 12 36270 90234 29448011
Toxicity to various agents 71.19 11.23 65 36217 173596 29364649
Oxygen saturation decreased 69.00 11.23 163 36119 44774 29493471
Middle insomnia 67.46 11.23 56 36226 5652 29532593
Therapeutic product effect incomplete 67.46 11.23 149 36133 39156 29499089
Respiratory distress 65.93 11.23 131 36151 31975 29506270
Bronchitis 65.82 11.23 142 36140 36726 29501519
Nasal congestion 65.16 11.23 97 36185 18782 29519463
Toxic epidermal necrolysis 65.15 11.23 95 36187 18058 29520187
Lung consolidation 64.92 11.23 52 36230 4991 29533254
Drug abuse 63.05 11.23 11 36271 79872 29458373
Respiratory disorder 59.68 11.23 88 36194 16895 29521350
Lower respiratory tract infection 59.13 11.23 112 36170 26390 29511855
Osteopenia 58.00 11.23 45 36237 4123 29534122
Respiratory failure 56.90 11.23 253 36029 96878 29441367
Eosinophilia 56.20 11.23 99 36183 22062 29516183
Painful respiration 50.67 11.23 26 36256 1148 29537097
Sleep disorder due to a general medical condition 48.26 11.23 36 36246 3110 29535135
Throat irritation 47.09 11.23 56 36226 8729 29529516
Dyspnoea exertional 43.17 11.23 120 36162 36370 29501875
Tachypnoea 41.57 11.23 70 36212 15045 29523200
Fractional exhaled nitric oxide increased 41.21 11.23 16 36266 360 29537885
Chest injury 40.50 11.23 24 36258 1409 29536836
Bronchospasm 39.99 11.23 54 36228 9555 29528690
Walking aid user 37.26 11.23 23 36259 1454 29536791
Pleural thickening 36.82 11.23 14 36268 297 29537948
Pulmonary mass 33.94 11.23 53 36229 10695 29527550
Pulmonary function test abnormal 32.33 11.23 24 36258 2058 29536187
Genital herpes simplex 31.62 11.23 10 36272 119 29538126
General physical health deterioration 30.87 11.23 224 36058 102633 29435612
Hypoventilation 29.74 11.23 26 36256 2815 29535430
Hyperkaliuria 29.43 11.23 9 36273 95 29538150
Ventricular fibrillation 29.41 11.23 62 36220 15771 29522474
Hypercapnia 29.16 11.23 29 36253 3697 29534548
Foetal exposure during pregnancy 28.21 11.23 4 36278 33863 29504382
Secretion discharge 27.95 11.23 30 36252 4180 29534065
Febrile neutropenia 27.94 11.23 60 36222 112180 29426065
Total lung capacity abnormal 27.12 11.23 9 36273 126 29538119
Diarrhoea 26.85 11.23 270 36012 332428 29205817
Sensitivity to weather change 25.79 11.23 18 36264 1401 29536844
Abdominal distension 24.91 11.23 117 36165 45794 29492451
Oral candidiasis 24.76 11.23 46 36236 10676 29527569
Multiple organ dysfunction syndrome 24.73 11.23 147 36135 62969 29475276
COVID-19 treatment 24.59 11.23 10 36272 255 29537990
Overdose 24.00 11.23 38 36244 79781 29458464
Eye disorder 23.86 11.23 38 36244 7796 29530449
Wolff-Parkinson-White syndrome 23.45 11.23 9 36273 196 29538049
Upper-airway cough syndrome 22.81 11.23 23 36259 2980 29535265
Bronchitis viral 22.75 11.23 9 36273 213 29538032
Product prescribing error 22.13 11.23 60 36222 17916 29520329
Feeling cold 21.94 11.23 40 36242 9151 29529094
Blood immunoglobulin E decreased 21.80 11.23 6 36276 42 29538203
Dust allergy 21.60 11.23 11 36271 478 29537767
Aortic aneurysm 21.51 11.23 32 36250 6188 29532057
Infective pulmonary exacerbation of cystic fibrosis 21.45 11.23 32 36250 6204 29532041
Lung hyperinflation 21.39 11.23 13 36269 799 29537446
Forced vital capacity decreased 21.15 11.23 12 36270 649 29537596
Off label use 21.09 11.23 252 36030 300548 29237697
Lung disorder 20.78 11.23 83 36199 30279 29507966
Tachycardia foetal 20.71 11.23 9 36273 272 29537973
Bronchial wall thickening 20.67 11.23 14 36268 1038 29537207
Chronic respiratory failure 20.62 11.23 15 36267 1247 29536998
Plantar fasciitis 20.41 11.23 15 36267 1266 29536979
White blood cell count decreased 20.37 11.23 45 36237 83317 29454928
Myoglobin blood increased 20.37 11.23 18 36264 1977 29536268
Ascites 20.36 11.23 94 36188 36525 29501720
Pneumonitis 20.28 11.23 78 36204 27966 29510279
Treatment failure 20.22 11.23 10 36272 36929 29501316
Genital herpes 20.18 11.23 11 36271 550 29537695
Respiratory tract congestion 19.60 11.23 28 36254 5221 29533024
Brain natriuretic peptide increased 19.50 11.23 25 36257 4205 29534040
Bronchial hyperreactivity 19.17 11.23 15 36267 1391 29536854
Respiratory acidosis 19.05 11.23 25 36257 4303 29533942
Medication error 18.75 11.23 63 36219 21148 29517097
Sensation of foreign body 17.97 11.23 16 36266 1774 29536471
Hyponatraemia 17.86 11.23 143 36139 67490 29470755
Pneumothorax 17.65 11.23 51 36231 15791 29522454
Intentional overdose 17.50 11.23 13 36269 38515 29499730
Aggression 17.47 11.23 11 36271 35530 29502715
Bilirubin conjugated abnormal 17.35 11.23 6 36276 96 29538149
Acute respiratory failure 17.13 11.23 71 36211 26331 29511914
Carbon dioxide increased 16.88 11.23 12 36270 962 29537283
Blood immunoglobulin E increased 16.82 11.23 16 36266 1931 29536314
Neuropathy peripheral 16.82 11.23 39 36243 70988 29467257
Hypohidrosis 16.74 11.23 7 36275 192 29538053
Respiratory tract infection 16.12 11.23 49 36233 15602 29522643
Peak expiratory flow rate decreased 16.11 11.23 6 36276 120 29538125
Influenza 16.05 11.23 97 36185 41784 29496461
Bronchospasm paradoxical 16.01 11.23 5 36277 57 29538188
Rales 15.83 11.23 31 36251 7479 29530766
Type IIa hyperlipidaemia 15.71 11.23 6 36276 129 29538116
Hypoxia 15.25 11.23 105 36177 47274 29490971
Rhinalgia 15.21 11.23 8 36274 372 29537873
Reversible airways obstruction 15.18 11.23 7 36275 244 29538001
Toxic optic neuropathy 14.89 11.23 10 36272 731 29537514
Malignant neoplasm progression 14.86 11.23 44 36238 73815 29464430
Long QT syndrome 14.83 11.23 16 36266 2242 29536003
Ocular discomfort 14.82 11.23 14 36268 1675 29536570
Platelet count decreased 14.80 11.23 72 36210 104600 29433645
Drug intolerance 14.57 11.23 23 36259 48356 29489889
Diaphragmatic disorder 14.53 11.23 11 36271 971 29537274
Subcutaneous emphysema 14.44 11.23 11 36271 981 29537264
Sneezing 14.26 11.23 22 36260 4392 29533853
Exposure via skin contact 14.18 11.23 4 36278 31 29538214
Status asthmaticus 14.17 11.23 7 36275 285 29537960
Neutropenia 14.14 11.23 99 36183 131612 29406633
Respiratory rate increased 13.80 11.23 32 36250 8676 29529569
Suicide attempt 13.66 11.23 13 36269 34097 29504148
Back injury 13.62 11.23 19 36263 3465 29534780
Breath sounds abnormal 13.34 11.23 24 36258 5433 29532812
Psoriasis 13.24 11.23 12 36270 32215 29506030
Drug resistance 13.11 11.23 5 36277 21535 29516710
Vital capacity decreased 12.78 11.23 7 36275 353 29537892
Drug ineffective 12.71 11.23 344 35938 362826 29175419
Death 12.50 11.23 322 35960 341762 29196483
Occupational exposure to air contaminants 12.39 11.23 5 36277 125 29538120
Therapeutic product effect prolonged 12.36 11.23 6 36276 235 29538010
Foetal distress syndrome 12.22 11.23 10 36272 989 29537256
Tachycardia 12.10 11.23 139 36143 72271 29465974
Headache 12.07 11.23 146 36136 173861 29364384
Lung diffusion test decreased 11.98 11.23 8 36274 579 29537666
Seasonal allergy 11.92 11.23 22 36260 5080 29533165
Haemoptysis 11.86 11.23 71 36211 30479 29507766
Rhinovirus infection 11.78 11.23 17 36265 3199 29535046
Cytomegalovirus infection 11.66 11.23 7 36275 23208 29515037
Pancreatitis acute 11.37 11.23 8 36274 24377 29513868
Cyanosis 11.35 11.23 35 36247 11232 29527013
Blister rupture 11.27 11.23 5 36277 159 29538086

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Asthma 1448.93 10.47 1043 71132 94182 64332375
Wheezing 885.51 10.47 728 71447 79851 64346706
Chronic obstructive pulmonary disease 663.83 10.47 585 71590 70463 64356094
Obstructive airways disorder 656.08 10.47 376 71799 22809 64403748
Dyspnoea 524.48 10.47 1875 70300 716799 63709758
Full blood count abnormal 337.19 10.47 274 71901 29483 64397074
Productive cough 287.18 10.47 381 71794 72822 64353735
Cough 284.76 10.47 862 71313 301286 64125271
Pneumonia 267.26 10.47 1284 70891 558292 63868265
Completed suicide 215.96 10.47 8 72167 224406 64202151
Chest discomfort 205.66 10.47 422 71753 115684 64310873
Sputum discoloured 199.25 10.47 163 72012 17693 64408864
Asthma-chronic obstructive pulmonary disease overlap syndrome 196.61 10.47 66 72109 1059 64425498
Nasal congestion 152.41 10.47 254 71921 59404 64367153
Toxicity to various agents 150.93 10.47 112 72063 363401 64063156
Sleep disorder due to a general medical condition 147.72 10.47 100 72075 8134 64418423
Middle insomnia 142.51 10.47 117 72058 12760 64413797
Appendicolith 139.27 10.47 71 72104 3398 64423159
Forced expiratory volume decreased 129.43 10.47 86 72089 6781 64419776
Bronchiectasis 127.01 10.47 114 72061 14026 64412531
Respiratory failure 118.33 10.47 423 71752 160760 64265797
Pulmonary function test decreased 114.79 10.47 78 72097 6383 64420174
Dyspnoea exertional 110.96 10.47 251 71924 73479 64353078
Drug abuse 108.66 10.47 11 72164 132363 64294194
Nasal obstruction 105.59 10.47 44 72131 1315 64425242
Lower respiratory tract infection 105.31 10.47 287 71888 94327 64332230
Drug intolerance 104.17 10.47 40 72135 187952 64238605
Breath sounds abnormal 102.68 10.47 93 72082 11576 64414981
Therapeutic product effect incomplete 101.61 10.47 300 71875 103182 64323375
Oxygen saturation decreased 100.79 10.47 306 71869 106870 64319687
Bronchitis 94.43 10.47 302 71873 108441 64318116
Respiratory distress 91.13 10.47 189 71986 52142 64374415
Upper-airway cough syndrome 85.34 10.47 74 72101 8696 64417861
Synovitis 84.62 10.47 7 72168 99083 64327474
Bronchospasm 83.63 10.47 112 72063 21570 64404987
Hypercapnia 83.24 10.47 69 72106 7625 64418932
Nasal turbinate hypertrophy 82.09 10.47 29 72146 546 64426011
Eosinophilia 81.48 10.47 150 72025 37926 64388631
Bronchial neoplasm 73.52 10.47 25 72150 418 64426139
Respiratory disorder 73.20 10.47 139 72036 35972 64390585
Acute respiratory failure 70.71 10.47 166 72009 49768 64376789
Off label use 70.37 10.47 418 71757 632388 63794169
Drug ineffective 69.28 10.47 605 71570 839642 63586915
Alopecia 68.71 10.47 51 72124 165639 64260918
Treatment failure 67.84 10.47 23 72152 116793 64309764
Rheumatoid arthritis 67.57 10.47 51 72124 164243 64262314
Rhonchi 66.79 10.47 44 72131 3419 64423138
Tachypnoea 66.32 10.47 112 72063 26459 64400098
Ventricular failure 66.17 10.47 24 72151 489 64426068
Appendicitis 64.86 10.47 78 72097 13491 64413066
Hyper IgE syndrome 63.26 10.47 23 72152 472 64426085
Systemic lupus erythematosus 62.27 10.47 7 72168 77605 64348952
Infusion related reaction 61.53 10.47 56 72119 164411 64262146
Stress 60.83 10.47 177 71998 60357 64366200
Toxic epidermal necrolysis 59.80 10.47 130 72045 37036 64389521
Endometrial ablation 59.11 10.47 25 72150 776 64425781
Respiration abnormal 58.87 10.47 52 72123 6263 64420294
Sleep apnoea syndrome 58.21 10.47 113 72062 29719 64396838
Restrictive pulmonary disease 58.14 10.47 34 72141 2138 64424419
Blood immunoglobulin E increased 58.02 10.47 42 72133 3802 64422755
Hepatic enzyme increased 57.85 10.47 37 72138 129906 64296651
Emphysema 56.29 10.47 74 72101 13995 64412562
Rales 56.19 10.47 77 72098 15152 64411405
Lung hyperinflation 53.35 10.47 29 72146 1583 64424974
Blood test abnormal 53.22 10.47 69 72106 12874 64413683
Pain 53.16 10.47 382 71793 553129 63873428
Hypoxia 52.04 10.47 216 71959 87933 64338624
Contraindicated product administered 51.82 10.47 28 72147 107801 64318756
Arthropathy 51.75 10.47 36 72139 120931 64305626
Mycobacterium avium complex infection 50.44 10.47 39 72136 3901 64422656
Pemphigus 49.91 10.47 5 72170 60696 64365861
Haemoptysis 49.84 10.47 144 72031 48904 64377653
Bronchial haemorrhage 49.02 10.47 25 72150 1197 64425360
Pericarditis 46.87 10.47 7 72168 62509 64364048
Glossodynia 46.80 10.47 8 72167 64688 64361869
Joint swelling 46.44 10.47 108 72067 215274 64211283
Cardiogenic shock 46.12 10.47 108 72067 32319 64394238
Prolonged expiration 45.59 10.47 21 72154 802 64425755
Respiratory rate increased 45.39 10.47 77 72098 18254 64408303
Heart sounds 45.10 10.47 19 72156 584 64425973
Arthralgia 43.99 10.47 302 71873 441958 63984599
Febrile neutropenia 43.84 10.47 90 72085 187567 64238990
Bronchial disorder 43.55 10.47 28 72147 2087 64424470
Hypoventilation 43.54 10.47 43 72132 5963 64420594
Therapeutic product effect decreased 43.46 10.47 39 72136 115312 64311245
Sinus pain 43.03 10.47 30 72145 2559 64423998
Diarrhoea 42.60 10.47 562 71613 722142 63704415
Infective pulmonary exacerbation of cystic fibrosis 42.56 10.47 59 72116 11737 64414820
Status asthmaticus 42.34 10.47 21 72154 947 64425610
Rash 41.81 10.47 321 71854 458228 63968329
PCO2 increased 41.75 10.47 25 72150 1642 64424915
Oesophageal spasm 41.36 10.47 29 72146 2496 64424061
Lung consolidation 41.07 10.47 47 72128 7711 64418846
Intentional overdose 40.87 10.47 25 72150 89919 64336638
Respiratory acidosis 39.68 10.47 52 72123 9803 64416754
Rhinitis 39.07 10.47 54 72121 10711 64415846
Lung disorder 38.41 10.47 152 72023 60548 64366009
Respiratory tract infection 38.17 10.47 110 72065 37297 64389260
Pulmonary function test abnormal 37.65 10.47 30 72145 3134 64423423
Sight disability 37.42 10.47 11 72164 111 64426446
PO2 decreased 37.25 10.47 28 72147 2685 64423872
Upper respiratory tract infection 36.60 10.47 170 72005 72615 64353942
COVID-19 treatment 36.51 10.47 15 72160 432 64426125
Painful respiration 36.21 10.47 29 72146 3052 64423505
Cardiac murmur 36.10 10.47 54 72121 11509 64415048
Nasal polyps 36.08 10.47 31 72144 3598 64422959
Maternal exposure during pregnancy 35.42 10.47 33 72142 95851 64330706
Chest injury 35.40 10.47 26 72149 2407 64424150
Breast conserving surgery 35.28 10.47 16 72159 589 64425968
Cyanosis 33.95 10.47 76 72099 22079 64404478
Thermohypoaesthesia 33.92 10.47 10 72165 102 64426455
Vocal cord dysfunction 33.83 10.47 14 72161 411 64426146
Polycystic ovaries 33.56 10.47 24 72151 2131 64424426
Loss of personal independence in daily activities 33.37 10.47 165 72010 72289 64354268
Sinus tachycardia 33.18 10.47 95 72080 32093 64394464
Total lung capacity increased 32.88 10.47 16 72159 692 64425865
Overdose 32.81 10.47 82 72093 159484 64267073
Gastrooesophageal reflux disease 32.55 10.47 181 71994 82962 64343595
Influenza B virus test positive 32.53 10.47 13 72162 348 64426209
Influenza 31.66 10.47 216 71959 106315 64320242
Oesophageal pain 30.68 10.47 27 72148 3236 64423321
Airway peak pressure increased 29.90 10.47 12 72163 325 64426232
Kyphosis 29.14 10.47 23 72152 2370 64424187
Pulmonary hypertension 28.90 10.47 110 72065 43029 64383528
Sneezing 28.82 10.47 57 72118 15194 64411363
Peak expiratory flow rate decreased 28.59 10.47 14 72161 614 64425943
Rib deformity 28.41 10.47 9 72166 119 64426438
Exposure during pregnancy 28.38 10.47 27 72148 77648 64348909
Reversible airways obstruction 28.33 10.47 17 72158 1121 64425436
Throat clearing 28.26 10.47 18 72157 1320 64425237
Pneumonitis 27.84 10.47 121 72054 50244 64376313
Heart rate increased 27.52 10.47 197 71978 98478 64328079
Frustration tolerance decreased 27.31 10.47 34 72141 6091 64420466
Neuropathy peripheral 26.90 10.47 57 72118 117468 64309089
Venous pressure jugular increased 26.70 10.47 17 72158 1246 64425311
Blister 26.38 10.47 31 72144 80936 64345621
Atrial fibrillation 26.28 10.47 300 71875 170789 64255768
Abdominal discomfort 26.13 10.47 110 72065 182212 64244345
Asthmatic crisis 26.08 10.47 19 72156 1737 64424820
Sinus disorder 25.90 10.47 58 72117 16850 64409707
Hyperkaliuria 25.65 10.47 9 72166 166 64426391
Type 2 diabetes mellitus 25.53 10.47 90 72085 33930 64392627
Wolff-Parkinson-White syndrome 25.52 10.47 10 72165 254 64426303
Injection site erythema 25.41 10.47 25 72150 70775 64355782
Chronic respiratory failure 25.38 10.47 22 72153 2584 64423973
Product use issue 25.33 10.47 86 72089 151629 64274928
Swelling 25.29 10.47 93 72082 160125 64266432
Injection site bruising 25.23 10.47 5 72170 36368 64390189
Helicobacter infection 25.13 10.47 6 72169 38356 64388201
Bronchopulmonary aspergillosis allergic 25.11 10.47 18 72157 1604 64424953
Seasonal allergy 24.83 10.47 46 72129 11680 64414877
Injection site pain 24.69 10.47 55 72120 111353 64315204
Separation anxiety disorder 24.40 10.47 6 72169 28 64426529
Cardiac failure congestive 24.29 10.47 238 71937 130342 64296215
Wound 24.15 10.47 30 72145 76447 64350110
Total lung capacity decreased 24.15 10.47 18 72157 1704 64424853
Genital herpes simplex 23.93 10.47 10 72165 301 64426256
Lactose intolerance 23.75 10.47 19 72156 1997 64424560
Eye pruritus 23.54 10.47 47 72128 12612 64413945
Duodenal ulcer perforation 23.52 10.47 5 72170 34620 64391937
Drug-induced liver injury 23.43 10.47 12 72163 47631 64378926
Respiratory gas exchange disorder 23.22 10.47 13 72162 752 64425805
Respiratory tract congestion 23.16 10.47 54 72121 16111 64410446
Aortic aneurysm 23.12 10.47 35 72140 7539 64419018
Multiple organ dysfunction syndrome 22.49 10.47 192 71983 101221 64325336
Red blood cell sedimentation rate increased 22.29 10.47 4 72171 31231 64395326
Sputum purulent 22.25 10.47 15 72160 1211 64425346
Nausea 22.03 10.47 691 71484 785109 63641448
Drug resistance 22.01 10.47 6 72169 35096 64391461
Sensitivity to weather change 21.89 10.47 32 72143 6682 64419875
Dysphonia 21.62 10.47 106 72069 46276 64380281
Ventricular fibrillation 21.35 10.47 67 72108 23793 64402764
Pulmonary mass 21.09 10.47 67 72108 23949 64402608
Affective disorder 20.93 10.47 31 72144 6549 64420008
Multiple sclerosis relapse 20.77 10.47 10 72165 41125 64385432
Psoriasis 20.74 10.47 30 72145 71673 64354884
Granuloma 20.71 10.47 31 72144 6610 64419947
Oral candidiasis 20.61 10.47 65 72110 23147 64403410
Drug hypersensitivity 20.45 10.47 169 72006 237646 64188911
Osteopenia 20.21 10.47 50 72125 15490 64411067
FEV1/FVC ratio decreased 20.05 10.47 7 72168 127 64426430
Throat irritation 19.96 10.47 81 72094 32630 64393927
Laryngeal stenosis 19.95 10.47 12 72163 795 64425762
Multimorbidity 19.86 10.47 13 72162 999 64425558
White blood cell count decreased 19.78 10.47 100 72075 157737 64268820
Rectal prolapse 19.76 10.47 16 72159 1710 64424847
Humidity intolerance 19.73 10.47 9 72166 336 64426221
Bundle branch block left 19.56 10.47 38 72137 9996 64416561
Pneumonia viral 19.55 10.47 33 72142 7789 64418768
Cor pulmonale 19.53 10.47 17 72158 2008 64424549
Colitis ischaemic 19.42 10.47 45 72130 13369 64413188
Forced vital capacity decreased 19.39 10.47 15 72160 1501 64425056
Bronchospasm paradoxical 19.33 10.47 7 72168 142 64426415
Dyslipidaemia 19.25 10.47 36 72139 9206 64417351
Long QT syndrome 18.98 10.47 26 72149 5113 64421444
Peak expiratory flow rate abnormal 18.96 10.47 6 72169 79 64426478
Platelet count decreased 18.95 10.47 110 72065 167601 64258956
Chest pain 18.95 10.47 370 71805 235610 64190947
Fatigue 18.94 10.47 667 71508 748063 63678494
Blood pH decreased 18.93 10.47 24 72151 4378 64422179
Total lung capacity abnormal 18.72 10.47 7 72168 156 64426401
Subcutaneous emphysema 18.60 10.47 15 72160 1594 64424963
Injection site reaction 18.52 10.47 15 72160 46649 64379908
Bronchial hyperreactivity 18.24 10.47 18 72157 2494 64424063
Injection site swelling 18.09 10.47 12 72163 41341 64385216
Lung opacity 17.99 10.47 20 72155 3179 64423378
Diaphragmatic disorder 17.98 10.47 14 72161 1414 64425143
Palmar-plantar erythrodysaesthesia syndrome 17.93 10.47 5 72170 28814 64397743
Liver disorder 17.84 10.47 20 72155 53331 64373226
Carbon dioxide increased 17.79 10.47 16 72159 1973 64424584
Bilirubin conjugated abnormal 17.77 10.47 6 72169 98 64426459
Tachycardia 17.73 10.47 250 71925 149329 64277228
Malaise 17.70 10.47 574 71601 395673 64030884
Muscle injury 17.58 10.47 4 72171 26433 64400124
Suicide attempt 17.48 10.47 33 72142 70974 64355583
Cytomegalovirus infection 17.37 10.47 10 72165 37189 64389368
Pneumonia staphylococcal 17.35 10.47 23 72152 4383 64422174
Psoriatic arthropathy 17.07 10.47 14 72161 43267 64383290
Dust allergy 17.03 10.47 12 72163 1041 64425516
Brain hypoxia 16.92 10.47 11 72164 836 64425721
Eosinophil count increased 16.89 10.47 44 72131 14068 64412489
Neutropenia 16.86 10.47 179 71996 239445 64187112
Impaired healing 16.81 10.47 26 72149 60447 64366110
Hepatic function abnormal 16.62 10.47 29 72146 64284 64362273
Dystrophic calcification 16.55 10.47 6 72169 122 64426435
Injection site pruritus 16.51 10.47 11 72164 37815 64388742
Headache 16.44 10.47 459 71716 529008 63897549
Bronchial wall thickening 16.39 10.47 15 72160 1892 64424665
Basal cell carcinoma 16.35 10.47 7 72168 30831 64395726
Oedema peripheral 16.29 10.47 328 71847 209989 64216568
Hypohidrosis 16.26 10.47 7 72168 227 64426330
Rhinitis allergic 16.25 10.47 31 72144 8047 64418510
Irritable bowel syndrome 16.13 10.47 11 72164 37358 64389199
Intentional product use issue 15.95 10.47 54 72121 95310 64331247
Toxic optic neuropathy 15.80 10.47 11 72164 936 64425621
Rhinorrhoea 15.72 10.47 118 72057 59851 64366706
Pneumonia pseudomonal 15.45 10.47 23 72152 4880 64421677
Sopor 15.30 10.47 7 72168 29654 64396903
Hyponatraemia 15.27 10.47 242 71933 148097 64278460
Pupillary reflex impaired 15.24 10.47 18 72157 3055 64423502
Lymphoedema 15.20 10.47 34 72141 9871 64416686
Eosinophil count abnormal 15.14 10.47 9 72166 583 64425974
Pneumocystis jirovecii pneumonia 15.09 10.47 6 72169 27628 64398929
Drug ineffective for unapproved indication 15.07 10.47 8 72167 31125 64395432
C-reactive protein increased 15.03 10.47 55 72120 94854 64331703
Malignant neoplasm progression 15.01 10.47 70 72105 112801 64313756
Gastrointestinal disorder 14.87 10.47 51 72124 89658 64336899
Aspiration 14.73 10.47 47 72128 16838 64409719
Hip arthroplasty 14.67 10.47 3 72172 21348 64405209
Suicidal ideation 14.62 10.47 33 72142 66509 64360048
Lung neoplasm malignant 14.62 10.47 55 72120 21393 64405164
General physical health deterioration 14.58 10.47 315 71860 204110 64222447
Lactic acidosis 14.53 10.47 118 72057 61292 64365265
Abortion spontaneous 14.50 10.47 5 72170 25138 64401419
Neuromyelitis optica spectrum disorder 14.40 10.47 10 72165 847 64425710
Generalised tonic-clonic seizure 14.39 10.47 14 72161 39843 64386714
Discomfort 14.08 10.47 45 72130 80833 64345724
Type IIa hyperlipidaemia 14.07 10.47 6 72169 190 64426367
Heparin-induced thrombocytopenia 14.03 10.47 30 72145 8449 64418108
Bone marrow failure 13.93 10.47 20 72155 47932 64378625
Pneumothorax 13.90 10.47 59 72116 24239 64402318
Pneumonia respiratory syncytial viral 13.77 10.47 12 72163 1419 64425138
Walking aid user 13.75 10.47 25 72150 6256 64420301
Vascular parkinsonism 13.73 10.47 5 72170 103 64426454
Pancytopenia 13.64 10.47 99 72076 143210 64283347
Pneumonia haemophilus 13.57 10.47 10 72165 930 64425627
Disease progression 13.42 10.47 98 72077 141582 64284975
Stomatitis 13.41 10.47 70 72105 109535 64317022
Respiratory alkalosis 13.33 10.47 19 72156 3878 64422679
Product prescribing error 13.28 10.47 76 72099 35193 64391364
Catarrh 13.13 10.47 8 72167 542 64426015
Tracheomalacia 13.10 10.47 6 72169 226 64426331
Secretion discharge 13.00 10.47 36 72139 11928 64414629
Extrapyramidal disorder 12.92 10.47 3 72172 19549 64407008
Hyperlactacidaemia 12.86 10.47 21 72154 4823 64421734
Occupational exposure to air contaminants 12.83 10.47 5 72170 125 64426432
Tracheitis 12.78 10.47 11 72164 1279 64425278
Amaurosis 12.64 10.47 10 72165 1034 64425523
Depressive symptom 12.64 10.47 20 72155 4476 64422081
Tracheal disorder 12.52 10.47 7 72168 404 64426153
Supraventricular tachycardia 12.49 10.47 48 72127 18859 64407698
Nephrocalcinosis 12.46 10.47 11 72164 1323 64425234
Glycosylated haemoglobin decreased 12.30 10.47 8 72167 608 64425949
Musculoskeletal stiffness 12.27 10.47 84 72091 123122 64303435
Haematoma 12.12 10.47 91 72084 46159 64380398
Myelodysplastic syndrome 12.06 10.47 8 72167 27571 64398986
Pharyngeal mass 12.05 10.47 6 72169 273 64426284
Loss of consciousness 12.04 10.47 107 72068 148258 64278299
Cardiac disorder 12.01 10.47 105 72070 55711 64370846
C-reactive protein abnormal 11.95 10.47 9 72166 29038 64397519
Dry eye 11.93 10.47 9 72166 29010 64397547
Tumour hyperprogression 11.92 10.47 5 72170 152 64426405
Hypochloraemia 11.79 10.47 13 72162 2048 64424509
Oral herpes 11.79 10.47 5 72170 22147 64404410
Arthritis 11.73 10.47 51 72124 83763 64342794
Oesophageal motility disorder 11.63 10.47 7 72168 464 64426093
Infective exacerbation of chronic obstructive airways disease 11.63 10.47 14 72161 2424 64424133
Product use in unapproved indication 11.59 10.47 134 72041 176484 64250073
Knee arthroplasty 11.59 10.47 8 72167 26991 64399566
Visceral pain 11.57 10.47 3 72172 18 64426539
Neutrophil count decreased 11.41 10.47 46 72129 77150 64349407
Abdominal distension 11.19 10.47 160 72015 95834 64330723
Blood pressure fluctuation 11.17 10.47 26 72149 51845 64374712
Myocardial infarction 11.03 10.47 253 71922 165568 64260989
Hypertrophic cardiomyopathy 10.97 10.47 12 72163 1874 64424683
Idiopathic intracranial hypertension 10.94 10.47 14 72161 2579 64423978
Appetite disorder 10.85 10.47 23 72152 6438 64420119
Idiopathic pulmonary fibrosis 10.81 10.47 17 72158 3783 64422774
Mucosal inflammation 10.77 10.47 35 72140 62549 64364008
Intentional self-injury 10.72 10.47 10 72165 29034 64397523
Oropharyngeal pain 10.71 10.47 149 72026 88718 64337839
Acute myeloid leukaemia 10.68 10.47 9 72166 27454 64399103
Angle closure glaucoma 10.67 10.47 14 72161 2643 64423914
Bronchitis viral 10.57 10.47 9 72166 1031 64425526
Drug eruption 10.57 10.47 15 72160 36121 64390436
Decreased appetite 10.56 10.47 237 71938 281052 64145505
Blood immunoglobulin E abnormal 10.51 10.47 3 72172 27 64426530
Pancreatitis 10.49 10.47 33 72142 59574 64366983

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC R01AX03 RESPIRATORY SYSTEM
NASAL PREPARATIONS
DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE
Other nasal preparations
ATC R03AL01 RESPIRATORY SYSTEM
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
ADRENERGICS, INHALANTS
Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
ATC R03AL02 RESPIRATORY SYSTEM
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
ADRENERGICS, INHALANTS
Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
ATC R03BB01 RESPIRATORY SYSTEM
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS
Anticholinergics
FDA MoA N0000175370 Cholinergic Antagonists
FDA EPC N0000175574 Anticholinergic
MeSH PA D018927 Anti-Asthmatic Agents
MeSH PA D001993 Bronchodilator Agents
MeSH PA D018678 Cholinergic Agents
MeSH PA D018680 Cholinergic Antagonists
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D019141 Respiratory System Agents
CHEBI has role CHEBI:35523 bronchodilator
CHEBI has role CHEBI:48876 muscarinic antagonists
CHEBI has role CHEBI:53784 antispasmodics

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Bronchospasm indication 4386001
Chronic obstructive lung disease indication 13645005 DOID:3083
Bronchitis indication 32398004 DOID:6132
Allergic rhinitis indication 61582004
Nasal discharge indication 64531003
Pulmonary emphysema indication 87433001
Chronic Obstructive Pulmonary Disease with Bronchospasms indication
Asthma off-label use 195967001 DOID:2841
Asthma-chronic obstructive pulmonary disease overlap syndrome off-label use 10692761000119107
Ocular hypertension contraindication 4210003 DOID:9282
Hyperthyroidism contraindication 34486009 DOID:7998
Hypertensive disorder contraindication 38341003 DOID:10763
Hypokalemia contraindication 43339004
Conduction disorder of the heart contraindication 44808001
Ketoacidosis contraindication 56051008
Metabolic acidosis contraindication 59455009
Diabetes mellitus contraindication 73211009 DOID:9351
Paradoxical bronchospasm contraindication 102578005
Prolonged QT interval contraindication 111975006
Seizure disorder contraindication 128613002
Bladder outflow obstruction contraindication 236645006
Benign prostatic hyperplasia contraindication 266569009
Retention of urine contraindication 267064002
Angle-closure glaucoma contraindication 392291006 DOID:13550
Chronic myocardial ischemia contraindication 413844008 DOID:3393
Myocardial ischemia contraindication 414795007 DOID:3393
Congenital long QT syndrome contraindication 442917000




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 13.24 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Muscarinic acetylcholine receptor M3 GPCR ANTAGONIST Ki 9.29 WOMBAT-PK CHEMBL
Muscarinic acetylcholine receptor M2 GPCR Ki 8.82 WOMBAT-PK
Muscarinic acetylcholine receptor M4 GPCR Ki 9.18 WOMBAT-PK
Muscarinic acetylcholine receptor M5 GPCR Ki 8.77 WOMBAT-PK
Muscarinic acetylcholine receptor M1 GPCR Ki 9.31 WOMBAT-PK
Solute carrier family 22 member 2 Transporter IC50 4.82 WOMBAT-PK
Muscarinic acetylcholine receptor M2 GPCR Ki 9.11 CHEMBL
Muscarinic acetylcholine receptor M1 GPCR Ki 9.54 CHEMBL
Muscarinic acetylcholine receptor M3 GPCR Ki 9.74 CHEMBL

External reference:

IDSource
4019791 VUID
N0000147880 NUI
D02212 KEGG_DRUG
66985-17-9 SECONDARY_CAS_RN
4019341 VANDF
4019791 VANDF
C0027235 UMLSCUI
CHEBI:5956 CHEBI
X8M PDB_CHEM_ID
CHEMBL1621597 ChEMBL_ID
DB00332 DRUGBANK_ID
CHEMBL1464005 ChEMBL_ID
CHEMBL2134724 ChEMBL_ID
D009241 MESH_DESCRIPTOR_UI
6604365 PUBCHEM_CID
325 IUPHAR_LIGAND_ID
GR88G0I6UL UNII
1309404 RXNORM
4916 MMSL
6256 MMSL
d00265 MMSL
001750 NDDF
004943 NDDF
108624006 SNOMEDCT_US
372518007 SNOMEDCT_US
386881005 SNOMEDCT_US
725862005 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Ipratropium Bromide HUMAN PRESCRIPTION DRUG LABEL 1 0054-0045 SPRAY 21 ug NASAL ANDA 3 sections
Ipratropium Bromide HUMAN PRESCRIPTION DRUG LABEL 1 0054-0046 SPRAY 42 ug NASAL ANDA 16 sections
Ipratropium Bromide HUMAN PRESCRIPTION DRUG LABEL 1 0378-7970 SOLUTION 0.50 mg RESPIRATORY (INHALATION) ANDA 22 sections
Ipratropium Bromide and Albuterol Sulfate HUMAN PRESCRIPTION DRUG LABEL 2 0378-9671 SOLUTION 0.50 mg RESPIRATORY (INHALATION) ANDA 28 sections
Ipratropium Bromide and Albuterol Sulfate HUMAN PRESCRIPTION DRUG LABEL 2 0487-0201 SOLUTION 0.50 mg RESPIRATORY (INHALATION) ANDA 28 sections
Ipratropium Bromide HUMAN PRESCRIPTION DRUG LABEL 1 0487-9801 SOLUTION 0.50 mg RESPIRATORY (INHALATION) ANDA 22 sections
Ipratropium Bromide HUMAN PRESCRIPTION DRUG LABEL 1 0591-3798 SOLUTION 0.50 mg RESPIRATORY (INHALATION) ANDA 20 sections
Combivent Respimat HUMAN PRESCRIPTION DRUG LABEL 2 0597-0024 SPRAY, METERED 20 ug RESPIRATORY (INHALATION) NDA 27 sections
Atrovent HFA HUMAN PRESCRIPTION DRUG LABEL 1 0597-0087 AEROSOL, METERED 17 ug RESPIRATORY (INHALATION) NDA 29 sections
Ipratropium Bromide and Albuterol Sulfate HUMAN PRESCRIPTION DRUG LABEL 2 0781-7146 SOLUTION 0.50 mg RESPIRATORY (INHALATION) ANDA 28 sections
Ipratropium Bromide HUMAN PRESCRIPTION DRUG LABEL 1 0781-7157 SOLUTION 0.50 mg RESPIRATORY (INHALATION) ANDA 23 sections
Ipratropium Bromide HUMAN PRESCRIPTION DRUG LABEL 1 16714-526 SPRAY, METERED 21 ug NASAL ANDA 24 sections
Ipratropium Bromide HUMAN PRESCRIPTION DRUG LABEL 1 16714-527 SPRAY, METERED 42 ug NASAL ANDA 25 sections
Ipratropium Bromide HUMAN PRESCRIPTION DRUG LABEL 1 21695-911 SOLUTION 0.50 mg RESPIRATORY (INHALATION) ANDA 21 sections
Ipratropium bromide HUMAN PRESCRIPTION DRUG LABEL 1 24208-398 SPRAY, METERED 21 ug NASAL ANDA 27 sections
Ipratropium Bromide HUMAN PRESCRIPTION DRUG LABEL 1 24208-399 SPRAY, METERED 42 ug NASAL ANDA 25 sections
Ipratropium Bromide HUMAN PRESCRIPTION DRUG LABEL 1 42254-041 SOLUTION 0.50 mg RESPIRATORY (INHALATION) ANDA 19 sections
Ipratropium Bromide HUMAN PRESCRIPTION DRUG LABEL 1 42254-355 SPRAY, METERED 42 ug NASAL ANDA 25 sections
Ipratropium Bromide Human Prescription Drug Label 1 47335-706 SOLUTION 0.50 mg RESPIRATORY (INHALATION) ANDA 19 sections
Ipratropium Bromide Human Prescription Drug Label 1 47335-706 SOLUTION 0.50 mg RESPIRATORY (INHALATION) ANDA 19 sections
Ipratropium Bromide and Albuterol Sulfate Human Prescription Drug Label 2 47335-756 SOLUTION 0.50 mg RESPIRATORY (INHALATION) ANDA 22 sections
Ipratropium Bromide HUMAN PRESCRIPTION DRUG LABEL 1 50090-0668 SOLUTION 0.50 mg RESPIRATORY (INHALATION) ANDA 21 sections
AtroventHFA HUMAN PRESCRIPTION DRUG LABEL 1 50090-0961 AEROSOL, METERED 17 ug RESPIRATORY (INHALATION) NDA 25 sections
IPRATROPIUM BROMIDE AND ALBUTEROL SULFATE HUMAN PRESCRIPTION DRUG LABEL 2 50090-1382 SOLUTION 0.50 mg RESPIRATORY (INHALATION) ANDA 26 sections
Ipratropium Bromide and Albuterol Sulfate HUMAN PRESCRIPTION DRUG LABEL 2 50090-1669 SOLUTION 0.50 mg RESPIRATORY (INHALATION) ANDA 27 sections
Ipratropium Bromide and Albuterol Sulfate HUMAN PRESCRIPTION DRUG LABEL 2 50090-2567 SOLUTION 0.50 mg RESPIRATORY (INHALATION) ANDA 27 sections
IPRATROPIUM BROMIDE AND ALBUTEROL SULFATE HUMAN PRESCRIPTION DRUG LABEL 2 50090-4103 SOLUTION 0.50 mg RESPIRATORY (INHALATION) ANDA 26 sections
Ipratropium Bromide HUMAN PRESCRIPTION DRUG LABEL 1 50090-4185 SOLUTION 0.50 mg RESPIRATORY (INHALATION) ANDA 22 sections
Ipratropium Bromide HUMAN PRESCRIPTION DRUG LABEL 1 50090-5968 SPRAY, METERED 42 ug NASAL ANDA 24 sections
AtroventHFA HUMAN PRESCRIPTION DRUG LABEL 1 53002-8410 AEROSOL, METERED 17 ug RESPIRATORY (INHALATION) NDA 28 sections